Coronaviruses (CoV) are a large family of viruses that cause illnesses ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV).1 The current outbreak of coronavirus disease was first reported from Wuhan, China in December 2019. After cases were identified in several countries, a global health emergency was declared with over 167,000 cases and thousands of deaths.2 This was ultimately followed with the declaration of a pandemic by the World Health Organization (WHO) on March 11, 2020 due to cases in over 110 countries and territories around the world and the sustained risk of further global spread.
Risk factors for severe illness are not yet clear, although older patients and those with chronic medical conditions may be at higher risk.1 Testing methods for the SARS-CoV-2 are still developing and are highly complex. Current molecular methods involve significant specimen handling time and nucleic acid extraction methods.3
The Simplexa™ COVID-19 Direct kit allows for rapid results directly from nasopharyngeal swab (NPS) specimens, eliminating traditional RNA extraction steps. This enables faster turnaround times to help improve patient management and prevent further transmission of the disease.
To learn more about DiaSorin’s response to the COVID-19 outbreak, visit https://diasoringroup.com/.
1. Centers for Disease Control and Prevention. (2020). Coronavirus. Retrieved from https://www.cdc.gov/coronavirus/index.html.
2. World Health Organization. (2020). WHO statement on cases of COVID-19 surpassing 100 000. Retrieved from https://www.who.int/news-room/detail/07-03-2020-whostatement-on-cases-of-covid-19-surpassing-100-000.
3. Centers for Disease Control and Prevention. (2020). Real-time RT-PCR panel for detection 2019-novel coronavirus. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html.
Why to choose it
An easy to use sample to answer system – with no extraction required and utilizing an all-in-one reagent mix.
Results You Can Depend On
Simplexa™ COVID-19 Direct assay targets two different regions of the SARS-CoV-2 genome, the ORF1ab and S gene. This provides high sensitivity and helps prevent false negatives.
A simple workflow with minimal hands on time and results in a little more than an hour allows more efficient test reporting and patient management.
All You Need
The simplicity and flexibility of the LIAISON MDX system, combined with the Simplexa™ COVID-19 direct assay design is a major step towards fighting the COVID-19 global pandemic.
Simplexa™ COVID-19 Direct Kit
|Code MOL4150||Reactions 24|
Simplexa™ COVID-19 Positive Control Pack
|Code MOL4160||Reactions 10|
Do you want to place an order or request a trial?Discover More